Vitamin D analogs 17,20S(OH)2pD and 17,20R(OH)2pD are noncalcemic and exhibit antifibrotic activity.
Andrzej T Slominski,Wei Li,Syamal K Bhattacharya,Richard A Smith,Patti L Johnson,Jianjun Chen,Kathleen E Nelson,Robert C Tuckey,duane d miller,Yan Jiao,Weikuan Gu,Arnold E Postlethwaite
DOI: https://doi.org/10.1038/jid.2010.425
IF: 7.59
2011-01-01
Journal of Investigative Dermatology
Abstract:TO THE EDITOR The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), has a number of desirable properties in addition to its classical effect on bone and calcium metabolism. These include immunomodulatory, anti-inflammatory, and anti-fibrotic properties; however, its use is limited because of the toxic (calcemic) effect at therapeutically relevant doses (Szodoray et al., 2008; Bikle, 2010). Our goal in this and related studies has been to identify natural noncalcemic vitamin D analogs for use as therapeutic agents to treat diseases like scleroderma and/or autoimmune diseases. We embarked upon a strategy to produce such agents with a short or long side chain. Specifically, we defined a, to our knowledge previously unreported, steroidogenic pathway initiated by cleavage of the side chain of 7-dehydrocholestrol by P450scc to produce 7-dehydropregnenolone (7DHP), which could be further converted to hydroxy-5,7-dienal intermediates by classical steroidogenic enzymes (Slominski et al., 2004, 2009). An example of the latter is 17,20-dihydroxy7DHP (17,20(OH)27DHP) (Shackleton et al., 2002), for which we established a chemical route of synthesis (5Z with UVB-induced transformation to vitamin D-like 17,20-dihydroxypregnacalciferol,7E-3β,17,20-trihydroxy-9,10-secopregna-5,7,10 triene) (17,20(OH)2pD) and lumisterol-like structures (Zmijewski et al., 2009). As 17,20(OH)27DHP is produced in the body, at least under pathological conditions (Smith LemliOptiz syndrome) (Shackleton et al., 2002), and it can be transformed in the skin to corresponding secosteroids when exposed to UVB (Slominski et al., 2004; Zmijewski et al., 2009), these vitamin D-like hydroxyproducts are good candidates to serve as natural products, which by definition would have low toxicity. Supporting this, shortening of the side chain of vitamin D eliminates its calcemic activity (Holick et al., 1975). Thus, these, to our knowledge previously unreported, vitamin D analogs could serve as candidates for treatment of autoimmune or fibrosing diseases, as vitamin D3 displays well-documented effects on these conditions in animal models (Moro et al., 2008). 17,20(OH)2pD and lumisterol derivatives were synthesized as described previously (Zmijewski et al., 2009). For details, see Supplementary Figure S1 online. Female C57BL/6 mice, 6 weeks old, were purchased from Jackson Labs (Bar Harbor, ME) and maintained on a regular laboratory chow diet. The experiments were approved by the local IACUC. Mice were divided into groups of three to receive one of the following treatments by daily intraperitoneal injection for 14 days: sterile sesame oil (50 μl) (Sigma Chemical, St Louis, MO), or 3 μg kg−1 17,20R(OH)2pD or 17,20S(OH)2pD dissolved in 50 μl sterile sesame oil. Mice tolerated the injections well without signs of clinical distress. On day 15 mice were euthanized, and sera were obtained for measurement of total Ca2+ by atomic absorption spectrophotometry (Bhattacharya, 1977), inorganic phosphate by Malachite Green Assay Kit (Cayman Chemical, Ann Arbor, MI), and fibroblast growth factor (FGF)23 by ELISA (Immuntopics, San Clemente, CA). Bone mineral density and bone mineral content were determined for whole-body (excluding the head) and excised soft tissue-cleaned femurs by dual-energy X-ray absorptiometry, using a GE Lunar PIXImus (GE Lunar Corporation, Madison, WI); quality control and calibration were carried out within 24 hours of each scanning period. An Instron Universal Test System (Instron model 5567, Instron, Norwood, MA) was used for three-point bending (gap size, 7 mm) to determine the flexure stress of mouse femoral diaphyses. The load was applied at a constant displacement of 5 mm min−1 to failure. The femurs broke in the mid-diaphyseal region, and data were recorded as flexure stress in megapascals. Hearts, livers, spleens, and kidneys were processed for histology. Human dermal fibroblasts were grown in 24-well Costar tissue culture plates to assess the effect of vitamin D analogs on total collagen protein (Raghow et al., 1987), hyaluronan (Postlethwaite et al., 1989), type I collagen by ELISA (Chondrex, Redmond, WA), or Col1A1 mRNA by quantitative reverse transcriptase in real time. We previously showed that 20-hydroxyvitamin D3 (20(OH)D3) at a dose as high as 3.0 μg kg−1 in rats has no calcemic activity (calcium=10.4±1.5 mg dl−1 (mean±SD) vs. 9.3±1.3 mg dl−1 for control), whereas 1,25(OH)2D3 at the same dose had the expected strong calcemic effect, raising calcium concentration to 16.0±1.2 mg dl−1 (Slominski et al., 2010). In this study, we have found that 17,20S(OH)2pD and 17,20R(OH)2pD at doses of 3 μg kg−1 had no significant effects on sera total Ca2+ levels (Table 1). Examination of histological sections of the hearts, kidneys, liver, and spleen revealed lack of calcifications or identifiable toxicity (not shown). Thus, 17,20R(OH)2pD and 17,20R(OH)2pD show the same noncalcemic properties as the structurally similar 20(OH)pD (Holick et al., 1975) and 20(OH)D3 (Slominski et al., 2010). Serum levels of the phosphatonin factor, FGF23, were not different in mice treated with sesame oil or 17,20S(OH)2pD (Table 1). However, 17,20R(OH)2pD did induce a significant elevation in serum levels of FGF23 (Table 1). When rats were administered 1,25(OH)2D3, serum levels of FGF23 increase dramatically (>5-fold increase by 0.3 μg kg−1 1,25(OH)2D3) and inorganic phosphate in sera is markedly reduced (Saito et al., 2005). In vitro, addition of 1,25(OH)2D3 to cultures of osteoblasts increases FGF23 mRNA levels (Liu et al., 2006). In this study, levels of inorganic phosphate in sera were not significantly different between mice treated with sesame oil versus 17,20R(OH)2pD or 17,20S(OH)2pD (Table 1). The data suggest that 17,20R(OH)2pD has retained a weak ability to modestly increase FGF23 levels in serum, but not sufficiently high to significantly reduce serum inorganic phosphate, whereas 17,20S(OH)2pD does not possess this FGF23-regulatory property of 1,25(OH)2D3. There were no differences in bone mineral density, bone mineral content, or flexure stress between 17,20S(OH)2D3-, 17,20R(OH)2D3-, and sesame oil-treated mice (Table 1). Table 2 shows that R and S forms of 17,20(OH)2pD and 17,20-dihydroxypregnalumisterol (17,20(OH)2pL), like 1,25(OH)2D3, significantly inhibit TGF-β1-induced total collagen protein and hyaluronan production by human dermal fibroblasts. We found no significant differences in fibroblast numbers per well and no significant differences in trypan blue exclusion. In agreement, 10−7 M 17,20S(OH)2pD or 17,20R(OH)2pD inhibited the TGF-β1-stimulated expression of Col1A1 mRNA (Supplementary Figure S2 online), and secreted type I collagen protein (Supplementary Figure S2 online, inset). In conclusion, dihydroxy secosteroidal derivatives with a short side chain (which are to our knowledge previously unreported) are noncalcemic and exhibit antifibrotic activity; therefore, they are excellent candidates for further testing in in vivo models of fibrosis and scleroderma. The authors state no conflict of interest. This work was supported by NIH/NIAMS Grant R01A052190 (AS) and a Merit Review Award from the US Department of Veteran Affairs (AEP). SUPPLEMENTARY MATERIAL Supplementary material is linked to the online version of the paper